Can you provide the last earnings date for GSK PLC-SPON ADR?
GSK PLC-SPON ADR (GSK) last reported earnings on 2/4/2026.
GSK PLC-SPON ADR (GSK) Earnings History & Surprises
NYSE:GSK • US37733W2044
Current stock price
53.94 USD
-0.76 (-1.39%)
At close:
54.35 USD
+0.41 (+0.76%)
After Hours:
GSK Earnings overview
Past quarterly earnings results for GSK PLC-SPON ADR (GSK), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- Apr 29, 2026
- Period
- Q1 / 2026
- EPS Estimate
- £0.90
- Revenue Estimate
- 7.886B
Last Reported
Most Recent- Release Date
- Feb 4, 2026
- Period
- Q4 / 2025
- EPS Reported
- £0.52
- EPS Surprise
- 8.69%
- Revenue Surprise
- -1.24%
Beat Rate
Last 8 Quarters 69%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in GBP): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 0.52 | 0.48 | 8.69% | 9.91% | 8.618B | 8.726B | -1.24% | 6.17% |
| Q3 2025 | 1.12 | 0.99 | 12.80% | 10.66% | 8.547B | 8.571B | -0.28% | 6.68% |
| Q2 2025 | 0.95 | 0.88 | 7.67% | 7.14% | 7.986B | 7.989B | -0.04% | 1.29% |
| Q1 2025 | 0.91 | 0.83 | 9.85% | 4.18% | 7.516B | 7.638B | -1.60% | 2.08% |
| Q4 2024 | 0.47 | 0.40 | 18.46% | -19.72% | 8.117B | 7.983B | 1.68% | 0.81% |
| Q3 2024 | 1.01 | 0.91 | 10.89% | -1.39% | 8.012B | 8.298B | -3.45% | -1.66% |
| Q2 2024 | 0.88 | 0.80 | 11.14% | 11.86% | 7.884B | 7.695B | 2.46% | 9.84% |
| Q1 2024 | 0.88 | 0.76 | 14.88% | 16.49% | 7.363B | 7.279B | 1.15% | 5.93% |
| Q4 2023 | 0.59 | 0.60 | -1.98% | 12.02% | 8.052B | 7.513B | 7.17% | 9.16% |
| Q3 2023 | 1.03 | 0.97 | 5.56% | 7.46% | 8.147B | 7.964B | 2.30% | 4.06% |
| Q2 2023 | 0.79 | 0.74 | 7.52% | 12.14% | 7.178B | 7.032B | 2.08% | 3.59% |
| Q1 2023 | 0.75 | 0.69 | 8.62% | -8.92% | 6.951B | 6.634B | 4.78% | -3.32% |
| Q4 2022 | 0.53 | 0.46 | 13.62% | -19.37% | 7.376B | 7.563B | -2.47% | 4.24% |
| Q3 2022 | 0.96 | 0.83 | 14.45% | 2.51% | 7.829B | 7.555B | 3.63% | 18.14% |
| Q2 2022 | 0.70 | 0.61 | 16.49% | -1.49% | 6.929B | 6.702B | 3.39% | 18.69% |
| Q1 2022 | 0.83 | 0.79 | 4.62% | 41.92% | 7.19B | 9.265B | -22.40% | -3.07% |
| Q4 2021 | 0.65 | 0.64 | 1.36% | 9.87% | 7.076B | 9.782B | -27.66% | -19.03% |
| Q3 2021 | 0.93 | 0.76 | 22.51% | 2.81% | 6.627B | 8.986B | -26.25% | -23.35% |
| Q2 2021 | 0.72 | 0.53 | 35.82% | 46.35% | 5.838B | 7.785B | -25.01% | -23.43% |
| Q1 2021 | 0.58 | 0.56 | 3.70% | -38.77% | 7.418B | 8.12B | -8.65% | -18.39% |
| Q4 2020 | 0.59 | 0.61 | -2.81% | - | 8.739B | 9.001B | -2.91% | - |
| Q3 2020 | 0.91 | 0.80 | 13.09% | - | 8.646B | 9.034B | -4.29% | - |
| Q2 2020 | 0.49 | 0.53 | -8.23% | - | 7.624B | 7.953B | -4.14% | - |
| Q1 2020 | 0.95 | 0.81 | 18.15% | - | 9.09B | 8.949B | 1.58% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
4
Average EPS beat (4)
9.75%
Max EPS beat (4)
12.80%
Min EPS beat (4)
7.67%
Revenue beat statistics
Revenue beat (4)
0
Average Revenue beat (4)
-0.79%
Max Revenue beat (4)
-0.04%
Min Revenue beat (4)
-1.60%
Analysis
In the last 4 quarters, GSK has consistently beaten EPS estimates in all releases
GSK has not beaten revenue estimates in any of the last 4 earnings releases
In the last 4 quarters, GSK has beaten the EPS estimates by 9.8% on average.
In the last 4 quarters, GSK reported -0.8% below the revenue estimates on average.
Related analysis
GSK PLC-SPON ADR / GSK Earnings FAQ
Did GSK PLC-SPON ADR (GSK) beat earnings estimates last quarter?
GSK PLC-SPON ADR (GSK) beat EPS estimates and missed revenue estimates in the most recent quarter.
How often does GSK PLC-SPON ADR (GSK) beat earnings estimates?
In the last 4 quarters, GSK PLC-SPON ADR (GSK) has beaten EPS estimates in 4 out of 4 releases.